How Is Optiscan Turning R&D Investment Into New Medical Imaging Breakthroughs?

• Revenue down 17.6% to $951,948 due to reduced orders from Carl Zeiss Meditec
• Net loss increased 4.1% to $6.31 million amid higher R&D and commercial expenses
• R&D tax incentive income surged 142% to $2.41 million, offsetting some costs
• Launched two new imaging devices – InForm™ for pathology and InSpecta™ for veterinary medicine